Ligand Pharmaceuticals Incorporated
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LGND research report →
Companywww.ligand.com
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression.
- CEO
- Todd C. Davis
- IPO
- 1992
- Employees
- 68
- HQ
- Jupiter, CA, US
Price Chart
Valuation
- Market Cap
- $4.36B
- P/E
- 28.19
- P/S
- 15.90
- P/B
- 4.34
- EV/EBITDA
- 18.51
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.61%
- Op Margin
- 36.72%
- Net Margin
- 55.95%
- ROE
- 16.19%
- ROIC
- 5.61%
Growth & Income
- Revenue
- $268.09M · 60.40%
- Net Income
- $124.45M · 3186.63%
- EPS
- $6.44 · 3027.27%
- Op Income
- $47.20M
- FCF YoY
- -36.82%
Performance & Tape
- 52W High
- $247.38
- 52W Low
- $98.89
- 50D MA
- $215.59
- 200D MA
- $192.15
- Beta
- 1.07
- Avg Volume
- 227.02K
Get TickerSpark's AI analysis on LGND
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | KOZARICH JOHN W | other | 1,575 |
| May 12, 26 | KOZARICH JOHN W | other | 459 |
| May 1, 26 | KOZARICH JOHN W | sell | 80 |
| May 1, 26 | KOZARICH JOHN W | sell | 1 |
| May 1, 26 | KOZARICH JOHN W | sell | 165 |
| May 1, 26 | KOZARICH JOHN W | sell | 105 |
| May 13, 26 | KOZARICH JOHN W | sell | 1,575 |
| May 1, 26 | KOZARICH JOHN W | sell | 116 |
| May 12, 26 | KOZARICH JOHN W | sell | 459 |
| May 12, 26 | KOZARICH JOHN W | other | 459 |
Our LGND Coverage
We haven't published any research on LGND yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LGND Report →